source
- Healthcare giants increasingly develop in-house AI tools instead of buying from startupsPanelists at the Digital Healthcare Innovation Summit in Boston highlighted a growing shift among large health‑care organizations toward creating their own artificial‑intelligence solutions. Rather…
- Intercept’s next-generation FXR agonist INT-787 fails Phase 2 trial in alcohol-associated hepatitisIntercept Pharmaceuticals reported that its experimental FXR agonist INT-787 did not demonstrate efficacy in a Phase 2 study of patients with severe alcohol-associated hepatitis. The trial results…